Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia


NCTID NCT06483802 (View at clinicaltrials.gov)
Description
Indication Friedreich Ataxia
Compound Name ASP2016
Sponsor Astellas Gene Therapies
Funder Type Industry
Status
Not yet recruiting
Enrollment Count 14

Therapy Information


Target Gene/Variant FXN
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Intravenous
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV8
Editor Type
Dose 1 Undisclosed dose escalation
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1
Submit Date 2024-06-26
Completion Date 2031-01-31
Last Update 2024-10-31

Participation Criteria


Eligible Age 18 Years - 40 Years
Standard Ages Adult
Eligible Sex ALL

Locations


No.of Trial Sites 5
Locations United States

Regulatory Information


Has US IND True
Recent Updates

Resources/Links